GSK "to pay $460 million" to settle bulk of US Avandia claims out of a total $2.4 billion Q2 legal bill
This article was originally published in Scrip
GlaxoSmithKline has reportedly agreed to pay around $460 million to resolve around 10,000 Avandia (rosiglitazone) lawsuits (out of the roughly 11,000 suits outstanding) from US patients or family members alleging that use of the product led to injury, according to the Bloomberg news service, citing people familiar with the accords. The figure pales next to the $2.36 billion GSK said it expected to record in legal charges during the second quarter in a statement released today by the pharma giant.
You may also be interested in...
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.
Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.
Nearly 500 shipments of illegal and unapproved prescription drugs and combination medical devices were seized at US borders thanks to Operation Broadsword.